Ticker Details
Celldex Therapeutics, Inc. Celldex Therapeutics Inc is a biopharmaceutical company. The company is engaged in the development and commercialization of immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.
IPO Date:	March 26, 1990
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$2.41B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.44 | 3.05%
Avg Daily Range (30 D):	$0.59 | 1.76%
Avg Daily Range (90 D):	$0.65 | 2.23%

Institutional Daily Volume
Avg Daily Volume:	1.11M
Avg Daily Volume (30 D):	.62M
Avg Daily Volume (90 D):	.72M

Trade Size
Avg Trade Size (Sh.):	156
Avg Trade Size (Sh.) (30 D):	52
Avg Trade Size (Sh.) (90 D):	57

Institutional Trades
Total Institutional Trades:	4,888
Avg Institutional Trade:	$2.14M
Avg Institutional Trade (30 D):	$2.78M
Avg Institutional Trade (90 D):	$2.92M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$2.94M
Avg Closing Trade (30 D):	$3.81M
Avg Closing Trade (90 D):	$4.5M
Avg Closing Volume:	81.34K

News

Apr 6, 2026 @ 2:53 PM Celldex Therapeutics Announces Closing of Public O... Source: Celldex Therapeutics, Inc.

Apr 2, 2026 @ 1:48 AM Celldex Announces Pricing of $300 Million Public O... Source: Na

Mar 1, 2026 @ 2:45 PM Celldex Presents Positive Data Demonstrating Barzo... Source: Celldex

Feb 27, 2026 @ 7:45 PM Celldex Presents Additional Positive Data from Pha... Source: Na

Aug 27, 2025 @ 8:50 AM Chronic Inducible Urticaria (CIndU) Market Researc... Source: Researchandmarkets.Com

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-4.27	$-1.18	$-1.23
Diluted EPS	$-4.27	$-1.18	$-1.23
Revenue	$.87M	$.02M	$.12M
Gross Profit
Net Income / Loss	$-283.65M	$-78.69M	$-81.32M
Operating Income / Loss	$-309.06M	$-84.44M	$-87.15M
Cost of Revenue
Net Cash Flow	$18.59M	$6.86M	$-7.17M
PE Ratio

Splits
Feb 11, 2019	1:15
Mar 10, 2008	1:12
Mar 07, 2008	1:12